Stem Cell Therapy International Appoints Dr. David L. Stark as President in Anticipation of the Upcoming Merger With

TAMPA, FL and SEOUL, SOUTH KOREA, Apr 01 (MARKET WIRE)
--
Stem Cell Therapy International, Inc. (OTCBB: SCII) and Histostem Corp. (Korea
Histostem).

Stem Cell Therapy International (SCII) announced today it has appointed
Dr.David L. Stark as president in anticipation of the upcoming merger with
Histostem of Korea, one of the world's leading umbilical cord stem cell blood
banks and research companies in the field of stem cell treatments for various
illnesses. After the closing of the merger between SCII and Histostem the
name of the combined entities will be changed to AmStem International
Corporation and Dr. Stark will continue in his capacity as president and
member of the board of directors. Dr. Hoon Han of Histostem will be chairman of
the board and CEO of AmStem International.

"Dr. Stark is an internationally recognized research innovator," explains
Calvin
Cao, Chairman and CEO of SCII. Formerly the Director of the National Institute
of
Clinical Research (NICR), Dr. Stark has been responsible for the design,
organization and implementation of clinical trials for pharmaceutical and
device companies -- from multi-billion dollar corporations to small,
entrepreneurial start-ups. He has a broad background in designing, conducting,
and monitoring clinical trials of new pharmaceuticals and devices and he will
be able to use that experience in assisting AmStem to pursue the filing of
various stem cell treatment applications with the U.S. FDA as well as assist in
the
worldwide marketing of these stem treatments to physicians, hospitals and
clinics
in the numerous countries interested in these treatment modalities.

Dr. Stark's involvement as president will seek to establish AmStem
International
as a worldwide leader in meeting the growing need for transplant grade
umbilical cord blood stem cells -- which have been identified as a potential
treatment for more than 80 diseases ranging from leukemia to sickle cell
anemia. With over 80,000 umbilical cord blood units already on hand in the
current inventory of Histostem, Ltd., Dr. Stark will work to assist Dr. Hoon
Han, CEO of AmStem International, to oversee the ongoing collection and
preparation of donated umbilical cord blood in order to maintain a valuable
inventory of HLA (human leukocyte antigen) typed and tested stem cells; all
indexed in a dynamic new database platform to speed the matching process. This
current inventory of 80,000 umbilical cord blood units in the "public bank"
represents a potentially very valuable asset of AmStem International since a
single unit of public bank umbilical cord blood has been known to be sold on
world markets for as much as $25,000. "Although this makes units held in cord
blood banks among the world's most valuable commodities, we should not
speculate about future value which could be higher or lower than previous
reported prices depending upon various circumstances such as the length of
time it takes the FDA to approve stem cell procedures for use in the Unites
States," cautioned Dr. Stark, who went on to observe, "We can afford to be
patient since all of the 80,000 units are in a cryobank so they are
protected and can be used many years from now, if necessary."

Dr. Hoon Han, CEO and chairman of Histostem Ltd., expressed the strategic
value of
having Dr. Stark as President of AmStem International Corp. "David brings not
just a knowledge of stem cells, but the ability to leverage his knowledge of
the FDA regulatory requirements to rapidly develop and market this innovative
approach to umbilical cord blood stem cell banking, allowing us almost instantly
to be a major competitor in the international stem cell market."

About AmStem International Corp.

AmStem International Corp., as the merged businesses of Stem Cell Therapy
International and Histostem, Ltd. will be known, intends to take its place as a
world leader in the research community with the introduction of a new
platform for developing contaminant-free human stem cells that will serve as a
catalyst for bringing new medical therapies to market.

About Histostem, Ltd.

Histostem, Ltd. started in Seoul, Korea in 2000. To date it has treated more
than
500 patients with stem cells and currently has 56 full time employees and 28
part-time employees. Histostem's intellectual property portfolio consists of
five
patents that have been granted, and 6 patents pending. A comprehensive list of
Histostem's achievements can be found at the company website
http://www.histostem.co.kr (click on English version when entering the site).

Forward-Looking Statements. This press release contains "forward-looking
statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934. The information in this
news release includes certain forward-looking statements that are based upon
assumptions
that in the future may prove not to have been accurate and are subject to
significant risks and uncertainties, including statements as to the future
performance of the company. Although the company believes that the
expectations reflected in its forward-looking statements are reasonable, it
can give no assurance that such expectations or any of its forward-looking
statements will prove to be correct.

Contact:

For more information, please contact Stem Cell Therapy International, Inc.

Calvin Cao
Chairman and CEO
T: 813-600-4088
E: calvin@SCTIcorp.com

Copyright 2008, Market Wire, All rights reserved.

-0-